A new method to detect melanoma cells in blood without surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the Cytophone, a patented system designed to identify and count circulating melanoma cells in the bloodstream. By analyzing a significantly larger volume of blood than traditional tests, the Cytophone aims to detect these rare cells non-invasively, without the need for injections or incisions. The study seeks to establish a correlation between circulating tumor cell counts and the risk of melanoma metastasis, recurrence, and treatment efficacy, potentially allowing for earlier intervention in patients. The trial will involve patients with a confirmed diagnosis of melanoma who can provide informed consent and sit for the procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological documented diagnosis of melanoma;
* Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks;
* Must be able to sit for up to 60 minutes.

Exclusion Criteria:

* Unable to provide informed consent to participate in the study, such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study;
* Clinically relevant cardiovascular, hepatic, neurological (e.g., evidence of organic brain syndrome), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study;
* Persistent significant or severe infection, either acute or chronic;
* Pregnant or breast-feeding women or those who plan to become pregnant during the study;
* Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy;
* Any known history of severe preexisting constipation.

Where it's running

• SSM Health Dean Medical Group Specialty Services
  Madison, Wisconsin, United States Recruiting

Study contacts

• Study coordinator: James Golleher, MBA
• Email: jgolleher@cytoastra.com
• Phone: 5017658175

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line immunotherapy for metastatic melanoma in Slovenia with biomarker identification

  This study will try first-line immunotherapy in adults with metastatic melanoma in Slovenia and collect blood, stool, and fluid samples to find markers linked to treatment response.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07407166

• AI analysis of ECGs to detect structural heart disease

  This project will test whether AI can read traditional and wearable ECGs to find undiagnosed valve disease, pulmonary hypertension, and heart failure in adults.

  Recruiting at 6 sites Imperial College London · Bristol and 5 other locations · NCT07057466

• Long-term safety follow-up after RP1, RP2, or RP3 treatment

  This study will follow people with melanoma or other advanced solid tumors who previously received RP1, RP2, or RP3 to see if any delayed side effects appear over five years.

  Recruiting at 2 sites Replimune, Inc. · La Jolla, California and 1 other locations · NCT06887348

• Investigating OBX-115 for advanced solid tumors

  This study is testing a new treatment called OBX-115 to see if it can help adults with advanced solid tumors like metastatic melanoma and non-small cell lung cancer feel better and live longer.

  Recruiting at 13 sites Phase 1/2 Obsidian Therapeutics, Inc. · Tucson, Arizona and 13 other locations · NCT06060613

• Combining lifileucel with pembrolizumab for advanced melanoma treatment

  This study is testing if combining a new treatment called lifileucel with pembrolizumab can help people with advanced melanoma feel better compared to just using pembrolizumab alone.

  Recruiting at 71 sites Phase 3 Iovance Biotherapeutics, Inc. · Birmingham, Alabama and 81 other locations · NCT05727904

• Evaluating lifileucel in patients with advanced uveal melanoma and certain sarcomas

  This study is testing a new treatment called lifileucel to see if it can help people with advanced uveal melanoma and certain types of sarcomas feel better.

  Recruiting at 2 sites Phase 1 Memorial Sloan Kettering Cancer Center · Harrison, New York and 1 other locations · NCT05607095

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.